MedTrace Logo

Effects of Glucagon Like Peptide-1 on No-reflow

NCT02507128 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2015-07-23

No results posted yet for this study

Summary

The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).

Conditions

  • Acute ST-segment Elevation Myocardial Infarction

Interventions

DRUG

liraglutide

Liraglutide were taken 30 min before PCI.

DRUG

placebo

Placebo were taken 30 min before PCI.

Sponsors & Collaborators

  • Chen Wei Ren, MD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02507128 on ClinicalTrials.gov